University Health Network, Toronto
Trial Pipeline
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
NCT06442930
The STOP-MED CTRCD Trial
NCT06183437
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
NCT06050707
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT05592938
Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT05440851
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT04016389
10°C vs 4°C Lung Preservation RCT
NCT05898776
PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer
NCT03455608
Safety and Tolerability of Perampanel in Cervical Dystonia
NCT02131467
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 28 |
| Phase 4 | 1 |
What the Pipeline for University Health Network, Toronto Shows
According to the ClinicalTrials.gov registry, University Health Network, Toronto is linked to 67 US clinical trials across every stage of research activity. Of those, 64 studies are currently recruiting — about 96% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 3% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University Health Network, Toronto reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 29 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University Health Network, Toronto is Organ Preservation with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.